Pfizer Inc. $PFE Shares Bought by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,351,803 shares of the biopharmaceutical company’s stock after buying an additional 29,227 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Pfizer were worth $110,884,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of PFE. Citizens National Bank Trust Department raised its stake in Pfizer by 0.9% during the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after purchasing an additional 395 shares during the period. Peak Asset Management LLC lifted its position in shares of Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after purchasing an additional 402 shares in the last quarter. Community Bank & Trust Waco Texas raised its position in shares of Pfizer by 0.6% in the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after purchasing an additional 412 shares in the last quarter. Able Wealth Management LLC boosted its stake in Pfizer by 2.0% during the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after acquiring an additional 413 shares during the last quarter. Finally, Boltwood Capital Management raised its stake in shares of Pfizer by 0.7% in the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock valued at $1,485,000 after purchasing an additional 420 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Morgan Stanley dropped their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. HSBC restated a “buy” rating and set a $29.00 price target on shares of Pfizer in a research report on Wednesday, December 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Bank of America decreased their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $27.88.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer signed a licensing deal to use Novavax’s Matrix?M adjuvant for vaccine development, which could expand Pfizer’s vaccine capabilities without heavy internal R&D spend and supports future product launches. Novavax enters license agreement with Pfizer for vaccine development
• Positive Sentiment: Investor outlets highlighted Pfizer as a dividend buy, boosting the income case for long?term holders and attracting yield?focused demand. This supports a case for defensive inflows even amid growth concerns. 3 No-Brainer Dividend Stocks to Buy Right Now — Including Pfizer
• Neutral Sentiment: Analysts and outlets are reassessing Pfizer’s valuation and shareholder return profile as revenue mix shifts (lower COVID sales versus steady core drugs); this is prompting rotation rather than a clear buy/sell signal. Pfizer (PFE) Valuation Check As Investors Reassess Recent Shareholder Returns
• Neutral Sentiment: Q4 outlook commentary centers on growth from Eliquis and softer COVID?19 sales; investors will watch earnings for confirmation of non?oncology stability. What to Expect From Pfizer’s Non?Oncology Business in Q4?
• Negative Sentiment: Industry execs at the JPMorgan Healthcare Conference flagged drug?pricing pressure, looming patent cliffs and intense dealmaking — themes that weigh on growth visibility for big pharma, including Pfizer. Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
• Negative Sentiment: Pfizer is exiting its ~11.7% stake in HIV?focused ViiV Healthcare as Shionogi boosts its holding; the exit reduces Pfizer’s exposure to that growth area and signals a portfolio reshuffle that could concern some investors. Japan’s Shionogi boosts ViiV stake to 21.7% as Pfizer exits
• Negative Sentiment: CEO Albert Bourla said U.S. drug prices are coming down, reinforcing investor concerns about margin pressure from policy and pricing trends. Pfizer CEO Albert Bourla: U.S. drug prices are coming down

Pfizer Price Performance

PFE opened at $25.52 on Wednesday. The stock has a market capitalization of $145.07 billion, a P/E ratio of 14.83 and a beta of 0.47. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The company’s 50 day simple moving average is $25.38 and its 200-day simple moving average is $24.99.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.